{"schema_version":"secwatch.filing_event.v1","accession":"0001048477-23-000005","form_type":"8-K","ticker":"BMRN","cik":"0001048477","company_name":"BIOMARIN PHARMACEUTICAL INC","filed_at":"2023-02-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:43.661174+00:00","generated_at":"2026-06-18T23:11:37.763946+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"BioMarin reports record Q4 revenues $537.5M (+19% YoY); guides 2023 total rev $2.375-2.5B","bullets":["Q4 total revenues $537.5M, up 19% YoY; full year $2.096B, up 14%.","GAAP net loss improved to $0.2M in Q4 from $57.9M loss; full year net income $141.6M.","VOXZOGO full year revenues $169.1M, up from $5.9M in 2021; 1,264 children treated as of Jan 2023.","2023 guidance: total rev $2.375-2.5B, GAAP net income $155-205M, non-GAAP EPS $1.80-2.05.","ROCTAVIAN 2023 revenue guidance $100-200M; FDA PDUFA date March 31, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001048477-23-000005","json":"https://secwatch.observer/filing/0001048477-23-000005.json","markdown":"https://secwatch.observer/filing/0001048477-23-000005.md","text":"https://secwatch.observer/filing/0001048477-23-000005.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1048477/000104847723000005/0001048477-23-000005-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1048477/000104847723000005/bmrn-20230227.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T23:11:37.763946+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ff2bc5bcbd3b17deb996cf39702e408ad021a0de","claim":"BIOMARIN PHARMACEUTICAL INC updated its fourth quarter and full year ended December 31, 2022 guidance (reaffirmed).","evidence_excerpt":"On February 27, 2023, BioMarin Pharmaceutical Inc. (the Company) announced financial results for its fourth quarter ended December 31, 2022. The Company’s press release issued on February 27, 2023 is attached hereto as Exhibit 99.1 and is incorporated by reference herein.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1048477/000104847723000005/0001048477-23-000005-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter and full year ended December 31, 2022"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}